BioTime, Inc. Share Price Nyse
Equities
US09066L1052
Biotechnology & Medical Research
Sales 2024 * | 12.22M 968M | Sales 2025 * | 5.87M 465M | Capitalization | 194M 15.41B |
---|---|---|---|---|---|
Net income 2024 * | -29M -2.3B | Net income 2025 * | -32M -2.54B | EV / Sales 2024 * | 15.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 33.1 x |
P/E ratio 2024 * |
-7.92
x | P/E ratio 2025 * |
-5.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.56% |
Latest transcript on BioTime, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 13/11/22 |
Chief Operating Officer | - | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 30/06/09 |
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Deborah Andrews
BRD | Director/Board Member | 66 | 10/04/14 |
1st Jan change | Capi. | |
---|---|---|
+21.85% | 46.44B | |
+37.63% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |